Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M mutations after treatment with the first- and second-generation EGFR-TKIs. However, no study has evaluated its safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakao, Akira, Hiranuma, Osamu, Uchino, Junji, Sakaguchi, Chikara, Araya, Tomoyuki, Hiraoka, Noriya, Ishizuka, Tamotsu, Takeda, Takayuki, Kawasaki, Masayuki, Goto, Yasuhiro, Imai, Hisao, Hattori, Noboru, Nakatomi, Keita, Uramoto, Hidetaka, Uryu, Kiyoaki, Fukuda, Minoru, Uchida, Yasuki, Yokoyama, Toshihide, Akai, Masaya, Mio, Tadashi, Nagashima, Seiji, Chihara, Yusuke, Tamiya, Nobuyo, Kaneko, Yoshiko, Mouri, Takako, Yamada, Tadaaki, Yoshimura, Kenichi, Fujita, Masaki, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356339/
https://www.ncbi.nlm.nih.gov/pubmed/32517152
http://dx.doi.org/10.3390/jcm9061762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356339/
https://www.ncbi.nlm.nih.gov/pubmed/32517152
http://dx.doi.org/10.3390/jcm9061762

Ejemplares similares